☰

Barry J. Kappel, Ph.D. - Publications

Affiliations: 
2006 Weill Cornell Medical College, New York, NY, United States 
Area:
Immunology, Pharmacology, Pathology
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Rotolo JA, Ramirez R, Koester M, Leong S, Ghamsari L, Merutka G, Kappel BJ. Abstract 2050: Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo Cancer Research. 79: 2050-2050. DOI: 10.1158/1538-7445.Am2019-2050  0.413
2010 Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. Journal of Liposome Research. 20: 330-40. PMID 20070139 DOI: 10.3109/08982100903544185  0.469
2007 Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers Bioconjugate Chemistry. 18: 2061-2067. PMID 17935286 DOI: 10.1021/Bc070075T  0.493
2007 Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. The Journal of Clinical Investigation. 117: 2422-30. PMID 17717602 DOI: 10.1172/Jci32226  0.534
2007 McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1180-9. PMID 17607040 DOI: 10.2967/Jnumed.106.039131  0.526
2007 Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization Plos One. 2. PMID 17342201 DOI: 10.1371/Journal.Pone.0000267  0.502
2007 Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Erratum: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor (Journal of Clinical Investigation (2007) 117, (2422-2430) DOI: 10.1172/JCI32226)) Journal of Clinical Investigation. 117. DOI: 10.1172/Jci32226C1  0.482
2006 Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Leukemia. 20: 2025-2033. PMID 16990779 DOI: 10.1038/Sj.Leu.2404380  0.52
2006 Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 107: 2045-51. PMID 16269613 DOI: 10.1182/Blood-2005-07-2828  0.573
2005 Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8763-72. PMID 16361564 DOI: 10.1158/1078-0432.Ccr-05-0975  0.541
2005 Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Research. 65: 4888-95. PMID 15930310 DOI: 10.1158/0008-5472.Can-04-3096  0.478
2005 Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner IM, Pamer EG, van den Brink MR, Scheinberg DA. Remodeling Specific Immunity by Use of MHC-Tetramers Distinguishes Graft-Versus-Tumor Activity from Graft-Versus-Host-Disease. Blood. 106: 1300-1300. DOI: 10.1182/Blood.V106.11.1300.1300  0.585
2004 Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, Liu C, Murphy GJ, Heller G, van den Brink MR. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 103: 1542-7. PMID 14563643 DOI: 10.1182/Blood-2003-03-0957  0.361
2004 Kappel B, Eng J, Pinilla-Ibarz J, van den Brink M, Scheinberg D. Selective depletion of T cell clones responsible for GVHD in a murine model Biology of Blood and Marrow Transplantation. 10: 20-21. DOI: 10.1016/J.Bbmt.2003.12.076  0.522
2003 Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Greenberg AS, Kappel BJ, van den Brink MR. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. The Journal of Clinical Investigation. 112: 1095-107. PMID 14523046 DOI: 10.1172/Jci17865  0.411
2003 Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MR. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 101: 2440-5. PMID 12424195 DOI: 10.1182/Blood-2002-07-2109  0.443
2002 Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine. 8: 1433-7. PMID 12426560 DOI: 10.1038/Nm1202-797  0.468
2001 Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MR. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 98: 2256-65. PMID 11568014 DOI: 10.1182/Blood.V98.7.2256  0.344
2001 Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JL, Burakoff SJ, van den Brink MR. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 97: 2886-95. PMID 11313285 DOI: 10.1182/Blood.V97.9.2886  0.408
Show low-probability matches.